This is a summary of the European public assessment report (EPAR) for Rekovelle. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Rekovelle.
For practical information about using Rekovelle, patients should read the package leaflet or contact their doctor or pharmacist.
Rekovelle : EPAR - Summary for the public (PDF/78 KB)
First published: 27/01/2017
Last updated: 27/01/2017
|Agency product number||
|International non-proprietary name (INN) or common name||
|Therapeutic area (MeSH)||
|Anatomical therapeutic chemical (ATC) code||
Ferring Pharmaceuticals A/S
|Date of issue of marketing authorisation valid throughout the European Union||
18/05/2017 Rekovelle - EMEA/H/C/003994 - II/0003/G
- Annex I - Summary of product characteristics
- Annex IIA - Manufacturing-authorisation holder responsible for batch release
- Annex IIB - Conditions of the marketing authorisation
- Annex IIIA - Labelling
- Annex IIIB - Package leaflet
Please note that the size of the above document can exceed 50 pages.
You are therefore advised to be selective about which sections or pages you wish to print.
Sex hormones and modulators of the genital system
Controlled ovarian stimulation for the development of multiple follicles in women undergoing assisted reproductive technologies (ART) such as an in vitro fertilisation (IVF) or intracytoplasmic sperm injection (ICSI) cycle.